Cargando…

Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator

ABSTRACT: For patients with non-cirrhotic liver-based metabolic disorders, hepatocyte transplantation can be an effective treatment. However, long-term function of transplanted hepatocytes following infusion has not been achieved due to insufficient numbers of hepatocytes reaching the liver cell pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Charlotte, Dhawan, Anil, Iansante, Valeria, Filippi, Celine, Mitry, Ragai, Tang, Joanne, Walker, Simon, Fernandez DaCosta, Raquel, Sinha, Siddharth, Hughes, Robin D., Koulmanda, Maria, Fitzpatrick, Emer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440943/
https://www.ncbi.nlm.nih.gov/pubmed/30820592
http://dx.doi.org/10.1007/s00109-019-01747-3
_version_ 1783407455178326016
author Lee, Charlotte
Dhawan, Anil
Iansante, Valeria
Filippi, Celine
Mitry, Ragai
Tang, Joanne
Walker, Simon
Fernandez DaCosta, Raquel
Sinha, Siddharth
Hughes, Robin D.
Koulmanda, Maria
Fitzpatrick, Emer
author_facet Lee, Charlotte
Dhawan, Anil
Iansante, Valeria
Filippi, Celine
Mitry, Ragai
Tang, Joanne
Walker, Simon
Fernandez DaCosta, Raquel
Sinha, Siddharth
Hughes, Robin D.
Koulmanda, Maria
Fitzpatrick, Emer
author_sort Lee, Charlotte
collection PubMed
description ABSTRACT: For patients with non-cirrhotic liver-based metabolic disorders, hepatocyte transplantation can be an effective treatment. However, long-term function of transplanted hepatocytes following infusion has not been achieved due to insufficient numbers of hepatocytes reaching the liver cell plates caused by activation of the instant blood-mediated inflammatory reaction (IBMIR). Our aim was to determine if the natural immune modulator, alpha-1 antitrypsin (AAT), could improve engraftment of transplanted hepatocytes and investigate its mechanism of action. A tubing loop model was used to analyse activation of the IBMIR when human hepatocytes were in contact with ABO-matched blood and 4 mg/ml AAT. Platelet and white cell counts, complement and cytokine expression were analysed. To determine if AAT could improve short-term engraftment, female rats underwent tail vein injection of AAT (120 mg/kg) or water (control) prior to the intrasplenic transplantation of 2 × 10(7) male hepatocytes. At 48 h and 1 week, livers were collected for analysis. In our loop model, human hepatocytes elicited a significant drop in platelet count with thrombus formation compared to controls. Loops containing AAT and hepatocytes showed no platelet consumption and no thrombus formation. Further, AAT treatment resulted in reduced IL-1β, IL-6 and IFN-γ and increased IL-1RA compared to untreated loops. In vivo, AAT significantly improved engraftment of rat hepatocytes compared to untreated at 48 h. AAT infusion may inhibit the IBMIR, thus improving short-term engraftment of donor hepatocytes and potentially improve the outcomes for patients with liver-based metabolic disease. KEY MESSAGES: • Alpha-1 antitrypsin (AAT) acts as an immune modulator to improve the efficacy of hepatocyte transplantation. • Treatment with AAT decreased thrombus formation and pro-inflammatory cytokine expression in a tubing loop model. • AAT significantly improved engraftment of donor hepatocytes within the first 48 h post transplantation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00109-019-01747-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6440943
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-64409432019-04-15 Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator Lee, Charlotte Dhawan, Anil Iansante, Valeria Filippi, Celine Mitry, Ragai Tang, Joanne Walker, Simon Fernandez DaCosta, Raquel Sinha, Siddharth Hughes, Robin D. Koulmanda, Maria Fitzpatrick, Emer J Mol Med (Berl) Original Article ABSTRACT: For patients with non-cirrhotic liver-based metabolic disorders, hepatocyte transplantation can be an effective treatment. However, long-term function of transplanted hepatocytes following infusion has not been achieved due to insufficient numbers of hepatocytes reaching the liver cell plates caused by activation of the instant blood-mediated inflammatory reaction (IBMIR). Our aim was to determine if the natural immune modulator, alpha-1 antitrypsin (AAT), could improve engraftment of transplanted hepatocytes and investigate its mechanism of action. A tubing loop model was used to analyse activation of the IBMIR when human hepatocytes were in contact with ABO-matched blood and 4 mg/ml AAT. Platelet and white cell counts, complement and cytokine expression were analysed. To determine if AAT could improve short-term engraftment, female rats underwent tail vein injection of AAT (120 mg/kg) or water (control) prior to the intrasplenic transplantation of 2 × 10(7) male hepatocytes. At 48 h and 1 week, livers were collected for analysis. In our loop model, human hepatocytes elicited a significant drop in platelet count with thrombus formation compared to controls. Loops containing AAT and hepatocytes showed no platelet consumption and no thrombus formation. Further, AAT treatment resulted in reduced IL-1β, IL-6 and IFN-γ and increased IL-1RA compared to untreated loops. In vivo, AAT significantly improved engraftment of rat hepatocytes compared to untreated at 48 h. AAT infusion may inhibit the IBMIR, thus improving short-term engraftment of donor hepatocytes and potentially improve the outcomes for patients with liver-based metabolic disease. KEY MESSAGES: • Alpha-1 antitrypsin (AAT) acts as an immune modulator to improve the efficacy of hepatocyte transplantation. • Treatment with AAT decreased thrombus formation and pro-inflammatory cytokine expression in a tubing loop model. • AAT significantly improved engraftment of donor hepatocytes within the first 48 h post transplantation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00109-019-01747-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-02-28 2019 /pmc/articles/PMC6440943/ /pubmed/30820592 http://dx.doi.org/10.1007/s00109-019-01747-3 Text en © The Author(s) 2019 OpenAccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Lee, Charlotte
Dhawan, Anil
Iansante, Valeria
Filippi, Celine
Mitry, Ragai
Tang, Joanne
Walker, Simon
Fernandez DaCosta, Raquel
Sinha, Siddharth
Hughes, Robin D.
Koulmanda, Maria
Fitzpatrick, Emer
Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator
title Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator
title_full Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator
title_fullStr Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator
title_full_unstemmed Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator
title_short Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator
title_sort improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440943/
https://www.ncbi.nlm.nih.gov/pubmed/30820592
http://dx.doi.org/10.1007/s00109-019-01747-3
work_keys_str_mv AT leecharlotte improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator
AT dhawananil improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator
AT iansantevaleria improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator
AT filippiceline improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator
AT mitryragai improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator
AT tangjoanne improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator
AT walkersimon improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator
AT fernandezdacostaraquel improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator
AT sinhasiddharth improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator
AT hughesrobind improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator
AT koulmandamaria improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator
AT fitzpatrickemer improvingengraftmentofhepatocytetransplantationusingalpha1antitrypsinasanimmunemodulator